Replies to post #112888 on Biotech Values

[DewDiligence]

Absent any new information, I rate the cumulative probability of FDA approval of NVS/MNTA’s Copaxone ANDA by the end of 2011, 2012, 2013, and 2014, respectively, at 42%, 68%, 78%, and 84%. JMHO, FWIW